nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—bone cancer—ocular cancer	0.261	0.374	CtDrD
Methotrexate—muscle cancer—ocular cancer	0.231	0.33	CtDrD
Methotrexate—germ cell cancer—ocular cancer	0.207	0.297	CtDrD
Methotrexate—ABCC1—Dactinomycin—ocular cancer	0.0749	0.35	CbGbCtD
Methotrexate—ABCG2—Dactinomycin—ocular cancer	0.0501	0.234	CbGbCtD
Methotrexate—ABCC2—Carboplatin—ocular cancer	0.0373	0.174	CbGbCtD
Methotrexate—ABCG2—Carboplatin—ocular cancer	0.0337	0.157	CbGbCtD
Methotrexate—ABCB1—Dactinomycin—ocular cancer	0.0181	0.0844	CbGbCtD
Methotrexate—SLC22A8—optic choroid—ocular cancer	0.00146	0.0906	CbGeAlD
Methotrexate—FOLR1—eye—ocular cancer	0.00114	0.0708	CbGeAlD
Methotrexate—FOLR1—epithelium—ocular cancer	0.00104	0.0648	CbGeAlD
Methotrexate—FOLR1—lymphoid tissue—ocular cancer	0.000803	0.0499	CbGeAlD
Methotrexate—SLC46A1—eye—ocular cancer	0.00077	0.0478	CbGeAlD
Methotrexate—SLC19A1—lymphoid tissue—ocular cancer	0.000704	0.0437	CbGeAlD
Methotrexate—FPGS—retina—ocular cancer	0.00066	0.041	CbGeAlD
Methotrexate—ATIC—eye—ocular cancer	0.000644	0.04	CbGeAlD
Methotrexate—ATIC—retina—ocular cancer	0.000638	0.0397	CbGeAlD
Methotrexate—ATIC—epithelium—ocular cancer	0.000589	0.0366	CbGeAlD
Methotrexate—SLC46A1—lymphoid tissue—ocular cancer	0.000542	0.0337	CbGeAlD
Methotrexate—MTHFR—eye—ocular cancer	0.000478	0.0297	CbGeAlD
Methotrexate—FPGS—lymphoid tissue—ocular cancer	0.000469	0.0291	CbGeAlD
Methotrexate—SLCO3A1—retina—ocular cancer	0.000467	0.029	CbGeAlD
Methotrexate—ATIC—lymphoid tissue—ocular cancer	0.000454	0.0282	CbGeAlD
Methotrexate—Extravasation—Carboplatin—ocular cancer	0.00045	0.08	CcSEcCtD
Methotrexate—DHFR—eye—ocular cancer	0.000432	0.0269	CbGeAlD
Methotrexate—DHFR—retina—ocular cancer	0.000428	0.0266	CbGeAlD
Methotrexate—PGD—eye—ocular cancer	0.000416	0.0258	CbGeAlD
Methotrexate—PGD—retina—ocular cancer	0.000412	0.0256	CbGeAlD
Methotrexate—SLC16A1—eye—ocular cancer	0.000388	0.0241	CbGeAlD
Methotrexate—SLC16A1—retina—ocular cancer	0.000385	0.0239	CbGeAlD
Methotrexate—AOX1—eye—ocular cancer	0.000366	0.0228	CbGeAlD
Methotrexate—SLC16A1—epithelium—ocular cancer	0.000355	0.0221	CbGeAlD
Methotrexate—MTHFR—lymphoid tissue—ocular cancer	0.000337	0.0209	CbGeAlD
Methotrexate—Ulcerative stomatitis—Dactinomycin—ocular cancer	0.000316	0.0562	CcSEcCtD
Methotrexate—Raised liver function tests—Dactinomycin—ocular cancer	0.000316	0.0562	CcSEcCtD
Methotrexate—TYMS—lymphoid tissue—ocular cancer	0.000308	0.0191	CbGeAlD
Methotrexate—DHFR—lymphoid tissue—ocular cancer	0.000305	0.0189	CbGeAlD
Methotrexate—SLC22A8—eye—ocular cancer	0.000293	0.0182	CbGeAlD
Methotrexate—PGD—lymphoid tissue—ocular cancer	0.000293	0.0182	CbGeAlD
Methotrexate—ABCC10—lymphoid tissue—ocular cancer	0.000251	0.0156	CbGeAlD
Methotrexate—Febrile neutropenia—Dactinomycin—ocular cancer	0.000242	0.0431	CcSEcCtD
Methotrexate—Eruption—Dactinomycin—ocular cancer	0.000237	0.0422	CcSEcCtD
Methotrexate—Folliculitis—Dactinomycin—ocular cancer	0.000232	0.0413	CcSEcCtD
Methotrexate—Hepatotoxicity—Dactinomycin—ocular cancer	0.000189	0.0336	CcSEcCtD
Methotrexate—Necrosis—Dactinomycin—ocular cancer	0.000186	0.033	CcSEcCtD
Methotrexate—Extravasation—Dactinomycin—ocular cancer	0.000167	0.0297	CcSEcCtD
Methotrexate—Ulcer—Dactinomycin—ocular cancer	0.000154	0.0274	CcSEcCtD
Methotrexate—Infection—Carboplatin—ocular cancer	0.000139	0.0248	CcSEcCtD
Methotrexate—Aplastic anaemia—Dactinomycin—ocular cancer	0.000137	0.0243	CcSEcCtD
Methotrexate—Mouth ulceration—Dactinomycin—ocular cancer	0.000132	0.0234	CcSEcCtD
Methotrexate—Sepsis—Dactinomycin—ocular cancer	0.000127	0.0225	CcSEcCtD
Methotrexate—Pain—Carboplatin—ocular cancer	0.00012	0.0213	CcSEcCtD
Methotrexate—Hepatic failure—Dactinomycin—ocular cancer	0.000118	0.0209	CcSEcCtD
Methotrexate—Body temperature increased—Carboplatin—ocular cancer	0.000111	0.0197	CcSEcCtD
Methotrexate—Lethargy—Dactinomycin—ocular cancer	0.000108	0.0192	CcSEcCtD
Methotrexate—ABCB1—retina—ocular cancer	0.000102	0.00634	CbGeAlD
Methotrexate—Liver function test abnormal—Dactinomycin—ocular cancer	9.78e-05	0.0174	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Dactinomycin—ocular cancer	9.53e-05	0.0169	CcSEcCtD
Methotrexate—ABCB1—epithelium—ocular cancer	9.41e-05	0.00585	CbGeAlD
Methotrexate—Pancytopenia—Dactinomycin—ocular cancer	8.69e-05	0.0154	CcSEcCtD
Methotrexate—Neutropenia—Dactinomycin—ocular cancer	8.56e-05	0.0152	CcSEcCtD
Methotrexate—Pneumonia—Dactinomycin—ocular cancer	8.21e-05	0.0146	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Dactinomycin—ocular cancer	8.09e-05	0.0144	CcSEcCtD
Methotrexate—Stomatitis—Dactinomycin—ocular cancer	7.95e-05	0.0141	CcSEcCtD
Methotrexate—Agranulocytosis—Dactinomycin—ocular cancer	7.61e-05	0.0135	CcSEcCtD
Methotrexate—Hepatitis—Dactinomycin—ocular cancer	7.32e-05	0.013	CcSEcCtD
Methotrexate—Pharyngitis—Dactinomycin—ocular cancer	7.27e-05	0.0129	CcSEcCtD
Methotrexate—ABCB1—lymphoid tissue—ocular cancer	7.25e-05	0.00451	CbGeAlD
Methotrexate—Erythema multiforme—Dactinomycin—ocular cancer	6.93e-05	0.0123	CcSEcCtD
Methotrexate—Chills—Dactinomycin—ocular cancer	6.57e-05	0.0117	CcSEcCtD
Methotrexate—Alopecia—Dactinomycin—ocular cancer	6.47e-05	0.0115	CcSEcCtD
Methotrexate—Erythema—Dactinomycin—ocular cancer	6.38e-05	0.0113	CcSEcCtD
Methotrexate—Ill-defined disorder—Dactinomycin—ocular cancer	5.92e-05	0.0105	CcSEcCtD
Methotrexate—Anaemia—Dactinomycin—ocular cancer	5.89e-05	0.0105	CcSEcCtD
Methotrexate—Malaise—Dactinomycin—ocular cancer	5.75e-05	0.0102	CcSEcCtD
Methotrexate—Leukopenia—Dactinomycin—ocular cancer	5.71e-05	0.0101	CcSEcCtD
Methotrexate—Myalgia—Dactinomycin—ocular cancer	5.43e-05	0.00965	CcSEcCtD
Methotrexate—Discomfort—Dactinomycin—ocular cancer	5.36e-05	0.00953	CcSEcCtD
Methotrexate—Infection—Dactinomycin—ocular cancer	5.17e-05	0.00919	CcSEcCtD
Methotrexate—Thrombocytopenia—Dactinomycin—ocular cancer	5.1e-05	0.00906	CcSEcCtD
Methotrexate—Anorexia—Dactinomycin—ocular cancer	4.96e-05	0.00882	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Dactinomycin—ocular cancer	4.74e-05	0.00843	CcSEcCtD
Methotrexate—Decreased appetite—Dactinomycin—ocular cancer	4.52e-05	0.00804	CcSEcCtD
Methotrexate—Fatigue—Dactinomycin—ocular cancer	4.49e-05	0.00798	CcSEcCtD
Methotrexate—Pain—Dactinomycin—ocular cancer	4.45e-05	0.00791	CcSEcCtD
Methotrexate—Feeling abnormal—Dactinomycin—ocular cancer	4.29e-05	0.00762	CcSEcCtD
Methotrexate—Gastrointestinal pain—Dactinomycin—ocular cancer	4.26e-05	0.00756	CcSEcCtD
Methotrexate—Abdominal pain—Dactinomycin—ocular cancer	4.11e-05	0.00731	CcSEcCtD
Methotrexate—Body temperature increased—Dactinomycin—ocular cancer	4.11e-05	0.00731	CcSEcCtD
Methotrexate—Hypersensitivity—Dactinomycin—ocular cancer	3.83e-05	0.00682	CcSEcCtD
Methotrexate—Asthenia—Dactinomycin—ocular cancer	3.73e-05	0.00664	CcSEcCtD
Methotrexate—Diarrhoea—Dactinomycin—ocular cancer	3.56e-05	0.00633	CcSEcCtD
Methotrexate—MTHFR—Disease—MAML2—ocular cancer	3.47e-05	0.00053	CbGpPWpGaD
Methotrexate—PGD—Disease—CDKN2B—ocular cancer	3.45e-05	0.000527	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CDKN2B—ocular cancer	3.44e-05	0.000525	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—EP300—ocular cancer	3.39e-05	0.000518	CbGpPWpGaD
Methotrexate—AOX1—Disease—MAML2—ocular cancer	3.39e-05	0.000518	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—GNA11—ocular cancer	3.31e-05	0.000506	CbGpPWpGaD
Methotrexate—Vomiting—Dactinomycin—ocular cancer	3.31e-05	0.00588	CcSEcCtD
Methotrexate—DHFR—Cell Cycle, Mitotic—CDK4—ocular cancer	3.3e-05	0.000504	CbGpPWpGaD
Methotrexate—Rash—Dactinomycin—ocular cancer	3.28e-05	0.00583	CcSEcCtD
Methotrexate—ABCC1—Disease—SAG—ocular cancer	3.2e-05	0.00049	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—HDAC1—ocular cancer	3.16e-05	0.000483	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—MDM2—ocular cancer	3.16e-05	0.000482	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—E2F1—ocular cancer	3.15e-05	0.000482	CbGpPWpGaD
Methotrexate—ABCC3—NRF2 pathway—TGFB1—ocular cancer	3.15e-05	0.000482	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CDK2—ocular cancer	3.12e-05	0.000477	CbGpPWpGaD
Methotrexate—ABCC4—Ectoderm Differentiation—MYC—ocular cancer	3.11e-05	0.000475	CbGpPWpGaD
Methotrexate—Nausea—Dactinomycin—ocular cancer	3.09e-05	0.00549	CcSEcCtD
Methotrexate—DHFR—Disease—MAML2—ocular cancer	3.08e-05	0.000471	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—GNAQ—ocular cancer	3.08e-05	0.000471	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—MYC—ocular cancer	3.08e-05	0.00047	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TGFB1—ocular cancer	3.07e-05	0.000469	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CDK2—ocular cancer	3.04e-05	0.000465	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—CDK2—ocular cancer	3.01e-05	0.00046	CbGpPWpGaD
Methotrexate—ABCC4—NRF2 pathway—TGFB1—ocular cancer	2.96e-05	0.000453	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CDK4—ocular cancer	2.95e-05	0.000451	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—CDKN1B—ocular cancer	2.88e-05	0.00044	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CDK4—ocular cancer	2.88e-05	0.00044	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—RB1—ocular cancer	2.87e-05	0.000438	CbGpPWpGaD
Methotrexate—ABCG2—HIF-1-alpha transcription factor network—AKT1—ocular cancer	2.85e-05	0.000436	CbGpPWpGaD
Methotrexate—ABCC1—Disease—E2F5—ocular cancer	2.84e-05	0.000434	CbGpPWpGaD
Methotrexate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ocular cancer	2.82e-05	0.000431	CbGpPWpGaD
Methotrexate—ABCC1—Disease—E2F4—ocular cancer	2.78e-05	0.000425	CbGpPWpGaD
Methotrexate—ABCC1—Disease—RPL39—ocular cancer	2.72e-05	0.000416	CbGpPWpGaD
Methotrexate—ABCC1—Disease—RBL1—ocular cancer	2.72e-05	0.000416	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CDK2—ocular cancer	2.72e-05	0.000416	CbGpPWpGaD
Methotrexate—FPGS—Disease—MDM2—ocular cancer	2.68e-05	0.00041	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—CDKN1A—ocular cancer	2.66e-05	0.000406	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CDK4—ocular cancer	2.57e-05	0.000393	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—RB1—ocular cancer	2.56e-05	0.000392	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—EP300—ocular cancer	2.55e-05	0.00039	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HDAC1—ocular cancer	2.54e-05	0.000388	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—GNA11—ocular cancer	2.53e-05	0.000388	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—EP300—ocular cancer	2.53e-05	0.000387	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—ocular cancer	2.53e-05	0.000386	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—RB1—ocular cancer	2.5e-05	0.000382	CbGpPWpGaD
Methotrexate—ABCC2—NRF2 pathway—TGFB1—ocular cancer	2.5e-05	0.000382	CbGpPWpGaD
Methotrexate—AOX1—Disease—HDAC1—ocular cancer	2.48e-05	0.000379	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—GNA11—ocular cancer	2.48e-05	0.000379	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—ocular cancer	2.45e-05	0.000375	CbGpPWpGaD
Methotrexate—FPGS—Disease—CDKN1B—ocular cancer	2.45e-05	0.000375	CbGpPWpGaD
Methotrexate—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—ocular cancer	2.43e-05	0.000372	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—TP53—ocular cancer	2.43e-05	0.000371	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—GNAQ—ocular cancer	2.36e-05	0.00036	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—GNAQ—ocular cancer	2.3e-05	0.000352	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CDKN2B—ocular cancer	2.27e-05	0.000348	CbGpPWpGaD
Methotrexate—FPGS—Disease—CDKN1A—ocular cancer	2.26e-05	0.000346	CbGpPWpGaD
Methotrexate—DHFR—Disease—HDAC1—ocular cancer	2.25e-05	0.000345	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—GNA11—ocular cancer	2.25e-05	0.000344	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—E2F1—ocular cancer	2.25e-05	0.000344	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—CDK2—ocular cancer	2.24e-05	0.000343	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—RB1—ocular cancer	2.24e-05	0.000342	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—CDKN1B—ocular cancer	2.23e-05	0.000341	CbGpPWpGaD
Methotrexate—AOX1—Disease—CDKN2B—ocular cancer	2.22e-05	0.00034	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—MYC—ocular cancer	2.2e-05	0.000337	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PSPH—ocular cancer	2.2e-05	0.000336	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—TGFB1—ocular cancer	2.2e-05	0.000336	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TFDP1—ocular cancer	2.2e-05	0.000336	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—MDM2—ocular cancer	2.18e-05	0.000334	CbGpPWpGaD
Methotrexate—ALB—Platelet degranulation—TGFB1—ocular cancer	2.17e-05	0.000332	CbGpPWpGaD
Methotrexate—FPGS—Disease—EP300—ocular cancer	2.15e-05	0.000329	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	2.13e-05	0.000326	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—CCND1—ocular cancer	2.13e-05	0.000325	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—TGFB1—ocular cancer	2.13e-05	0.000325	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—EP300—ocular cancer	2.12e-05	0.000324	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—GNAQ—ocular cancer	2.09e-05	0.00032	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—MDM2—ocular cancer	2.09e-05	0.00032	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—TP53—ocular cancer	2.08e-05	0.000318	CbGpPWpGaD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—ocular cancer	2.07e-05	0.000316	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—CDKN1A—ocular cancer	2.06e-05	0.000315	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GNA11—ocular cancer	2.05e-05	0.000314	CbGpPWpGaD
Methotrexate—DHFR—Disease—CDKN2B—ocular cancer	2.02e-05	0.000309	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CDKN1B—ocular cancer	1.99e-05	0.000305	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GNA11—ocular cancer	1.97e-05	0.0003	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—EP300—ocular cancer	1.96e-05	0.000299	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CDKN1B—ocular cancer	1.95e-05	0.000298	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CDK2—ocular cancer	1.94e-05	0.000296	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PSPH—ocular cancer	1.93e-05	0.000295	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—TGFB1—ocular cancer	1.92e-05	0.000293	CbGpPWpGaD
Methotrexate—PGD—Disease—MDM2—ocular cancer	1.91e-05	0.000292	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—CDKN1B—ocular cancer	1.91e-05	0.000292	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GNAQ—ocular cancer	1.91e-05	0.000292	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—MDM2—ocular cancer	1.91e-05	0.000291	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CCND1—ocular cancer	1.9e-05	0.000291	CbGpPWpGaD
Methotrexate—FPGS—Disease—MYC—ocular cancer	1.87e-05	0.000287	CbGpPWpGaD
Methotrexate—FPGS—Disease—TGFB1—ocular cancer	1.87e-05	0.000286	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CCND1—ocular cancer	1.86e-05	0.000284	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CDKN1A—ocular cancer	1.84e-05	0.000281	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—ocular cancer	1.83e-05	0.00028	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GNAQ—ocular cancer	1.83e-05	0.000279	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GNA11—ocular cancer	1.8e-05	0.000276	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—EP300—ocular cancer	1.8e-05	0.000275	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—EP300—ocular cancer	1.8e-05	0.000275	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CDKN1A—ocular cancer	1.8e-05	0.000275	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—CDKN1A—ocular cancer	1.76e-05	0.000269	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—EP300—ocular cancer	1.75e-05	0.000268	CbGpPWpGaD
Methotrexate—PGD—Disease—CDKN1B—ocular cancer	1.75e-05	0.000267	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MAML2—ocular cancer	1.74e-05	0.000267	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CDKN1B—ocular cancer	1.74e-05	0.000266	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—HRAS—ocular cancer	1.73e-05	0.000265	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—EP300—ocular cancer	1.71e-05	0.000261	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—GNA11—ocular cancer	1.71e-05	0.000261	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—MYC—ocular cancer	1.71e-05	0.000261	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—EP300—ocular cancer	1.69e-05	0.000258	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GNAQ—ocular cancer	1.68e-05	0.000256	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—EP300—ocular cancer	1.68e-05	0.000256	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CCND1—ocular cancer	1.66e-05	0.000254	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GNA11—ocular cancer	1.63e-05	0.000249	CbGpPWpGaD
Methotrexate—PGD—Disease—CDKN1A—ocular cancer	1.61e-05	0.000246	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CDKN1A—ocular cancer	1.61e-05	0.000246	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—GNAQ—ocular cancer	1.59e-05	0.000243	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—AKT1—ocular cancer	1.54e-05	0.000236	CbGpPWpGaD
Methotrexate—PGD—Disease—EP300—ocular cancer	1.53e-05	0.000234	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—AKT1—ocular cancer	1.53e-05	0.000234	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—EP300—ocular cancer	1.53e-05	0.000234	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—MYC—ocular cancer	1.53e-05	0.000233	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GNAQ—ocular cancer	1.51e-05	0.000231	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—MYC—ocular cancer	1.49e-05	0.000228	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—AKT1—ocular cancer	1.48e-05	0.000226	CbGpPWpGaD
Methotrexate—FPGS—Disease—HRAS—ocular cancer	1.47e-05	0.000225	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TGFB1—ocular cancer	1.47e-05	0.000225	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—MYC—ocular cancer	1.46e-05	0.000223	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—TGFB1—ocular cancer	1.46e-05	0.000223	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HDAC1—ocular cancer	1.43e-05	0.000219	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GNA11—ocular cancer	1.42e-05	0.000217	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—EP300—ocular cancer	1.4e-05	0.000215	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—ocular cancer	1.36e-05	0.000208	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—ocular cancer	1.35e-05	0.000207	CbGpPWpGaD
Methotrexate—PGD—Disease—MYC—ocular cancer	1.34e-05	0.000204	CbGpPWpGaD
Methotrexate—PGD—Disease—TGFB1—ocular cancer	1.33e-05	0.000204	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—MYC—ocular cancer	1.33e-05	0.000204	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GNAQ—ocular cancer	1.32e-05	0.000201	CbGpPWpGaD
Methotrexate—FPGS—Disease—AKT1—ocular cancer	1.3e-05	0.000199	CbGpPWpGaD
Methotrexate—PGD—Metabolism—EP300—ocular cancer	1.28e-05	0.000196	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—AKT1—ocular cancer	1.28e-05	0.000196	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HDAC1—ocular cancer	1.28e-05	0.000195	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GNA11—ocular cancer	1.27e-05	0.000195	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MDM2—ocular cancer	1.26e-05	0.000193	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—EP300—ocular cancer	1.26e-05	0.000193	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—ocular cancer	1.25e-05	0.000192	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ocular cancer	1.24e-05	0.00019	CbGpPWpGaD
Methotrexate—AOX1—Disease—MDM2—ocular cancer	1.23e-05	0.000188	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—EP300—ocular cancer	1.22e-05	0.000187	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GNA11—ocular cancer	1.21e-05	0.000185	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—ocular cancer	1.21e-05	0.000185	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GNAQ—ocular cancer	1.19e-05	0.000181	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ocular cancer	1.18e-05	0.000181	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—HRAS—ocular cancer	1.16e-05	0.000177	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CDKN1B—ocular cancer	1.15e-05	0.000176	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—HRAS—ocular cancer	1.15e-05	0.000175	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—ocular cancer	1.14e-05	0.000175	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN2B—ocular cancer	1.14e-05	0.000175	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GNAQ—ocular cancer	1.13e-05	0.000172	CbGpPWpGaD
Methotrexate—AOX1—Disease—CDKN1B—ocular cancer	1.12e-05	0.000172	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GNA11—ocular cancer	1.12e-05	0.000171	CbGpPWpGaD
Methotrexate—DHFR—Disease—MDM2—ocular cancer	1.12e-05	0.000171	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TGFB1—ocular cancer	1.1e-05	0.000168	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—ocular cancer	1.09e-05	0.000167	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—ocular cancer	1.09e-05	0.000167	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—AKT1—ocular cancer	1.09e-05	0.000166	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—AKT1—ocular cancer	1.09e-05	0.000166	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CDKN1A—ocular cancer	1.06e-05	0.000162	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—ocular cancer	1.06e-05	0.000162	CbGpPWpGaD
Methotrexate—PGD—Disease—HRAS—ocular cancer	1.05e-05	0.00016	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GNAQ—ocular cancer	1.04e-05	0.000159	CbGpPWpGaD
Methotrexate—AOX1—Disease—CDKN1A—ocular cancer	1.04e-05	0.000159	CbGpPWpGaD
Methotrexate—DHFR—Disease—CDKN1B—ocular cancer	1.02e-05	0.000156	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—AKT1—ocular cancer	1.02e-05	0.000156	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—CDK2—ocular cancer	1.02e-05	0.000155	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—AKT1—ocular cancer	1.01e-05	0.000155	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EP300—ocular cancer	1.01e-05	0.000155	CbGpPWpGaD
Methotrexate—AOX1—Disease—EP300—ocular cancer	9.88e-06	0.000151	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—TGFB1—ocular cancer	9.62e-06	0.000147	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—EP300—ocular cancer	9.56e-06	0.000146	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ocular cancer	9.49e-06	0.000145	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—ocular cancer	9.47e-06	0.000145	CbGpPWpGaD
Methotrexate—DHFR—Disease—CDKN1A—ocular cancer	9.44e-06	0.000144	CbGpPWpGaD
Methotrexate—PGD—Disease—AKT1—ocular cancer	9.26e-06	0.000142	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—ocular cancer	9.09e-06	0.000139	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—ocular cancer	9.02e-06	0.000138	CbGpPWpGaD
Methotrexate—DHFR—Disease—EP300—ocular cancer	8.99e-06	0.000137	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MYC—ocular cancer	8.81e-06	0.000135	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TGFB1—ocular cancer	8.79e-06	0.000134	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—HRAS—ocular cancer	8.63e-06	0.000132	CbGpPWpGaD
Methotrexate—AOX1—Disease—MYC—ocular cancer	8.61e-06	0.000132	CbGpPWpGaD
Methotrexate—AOX1—Disease—TGFB1—ocular cancer	8.59e-06	0.000131	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AKT1—ocular cancer	8.48e-06	0.00013	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—EP300—ocular cancer	8.47e-06	0.000129	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—EP300—ocular cancer	8.27e-06	0.000126	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—ocular cancer	7.83e-06	0.00012	CbGpPWpGaD
Methotrexate—DHFR—Disease—TGFB1—ocular cancer	7.81e-06	0.000119	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ocular cancer	7.8e-06	0.000119	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—ocular cancer	7.76e-06	0.000119	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—ocular cancer	7.62e-06	0.000116	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—EP300—ocular cancer	7.53e-06	0.000115	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GNA11—ocular cancer	6.92e-06	0.000106	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HRAS—ocular cancer	6.92e-06	0.000106	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—EP300—ocular cancer	6.85e-06	0.000105	CbGpPWpGaD
Methotrexate—AOX1—Disease—HRAS—ocular cancer	6.76e-06	0.000103	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—ocular cancer	6.69e-06	0.000102	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	6.58e-06	0.000101	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—EP300—ocular cancer	6.57e-06	0.0001	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GNAQ—ocular cancer	6.43e-06	9.84e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MDM2—ocular cancer	6.34e-06	9.7e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—HRAS—ocular cancer	6.15e-06	9.4e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—ocular cancer	6.11e-06	9.34e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GNA11—ocular cancer	6.06e-06	9.27e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—EP300—ocular cancer	6.02e-06	9.21e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—ocular cancer	5.97e-06	9.12e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1B—ocular cancer	5.79e-06	8.85e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—EP300—ocular cancer	5.7e-06	8.72e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GNAQ—ocular cancer	5.64e-06	8.62e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—EP300—ocular cancer	5.44e-06	8.31e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—ocular cancer	5.43e-06	8.3e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1A—ocular cancer	5.34e-06	8.17e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—EP300—ocular cancer	5.19e-06	7.94e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—ocular cancer	5.12e-06	7.82e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EP300—ocular cancer	5.09e-06	7.77e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—ocular cancer	5e-06	7.64e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TGFB1—ocular cancer	4.96e-06	7.58e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—EP300—ocular cancer	4.73e-06	7.24e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—ocular cancer	4.55e-06	6.95e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—ocular cancer	4.43e-06	6.77e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TGFB1—ocular cancer	4.42e-06	6.76e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—EP300—ocular cancer	4.26e-06	6.51e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—ocular cancer	4.14e-06	6.33e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—ocular cancer	4.08e-06	6.24e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—EP300—ocular cancer	4.05e-06	6.19e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—ocular cancer	3.97e-06	6.07e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HRAS—ocular cancer	3.9e-06	5.97e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—EP300—ocular cancer	3.75e-06	5.73e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—ocular cancer	3.64e-06	5.57e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HRAS—ocular cancer	3.48e-06	5.32e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—ocular cancer	3.45e-06	5.27e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—ocular cancer	3.28e-06	5.02e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—ocular cancer	3.07e-06	4.7e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—ocular cancer	2.86e-06	4.37e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—ocular cancer	2.57e-06	3.93e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—ocular cancer	2.45e-06	3.74e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—EP300—ocular cancer	2.31e-06	3.54e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—ocular cancer	2.26e-06	3.46e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—EP300—ocular cancer	2.03e-06	3.1e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—ocular cancer	1.4e-06	2.14e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—ocular cancer	1.22e-06	1.87e-05	CbGpPWpGaD
